Medical Oncologist
Targeted treatment
Sacituzumab govitecan for triple-negative breast cancer
Sacituzumab govitecan is an antibody-drug conjugate that delivers chemotherapy to breast cancer cells carrying the Trop-2 protein. It helps women with pre-treated metastatic triple negative breast cancer live longer than standard chemotherapy. This page explains, in general terms, how it works and its side effects.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- What is sacituzumab govitecan and who is it for?
- What a treatment cycle usually involves
- Side effects most worth knowing about
- The vocabulary, in plain language
- What this treatment can and cannot do
- Staying ahead of loose motions and infection
- Where sacituzumab govitecan fits
- How an antibody-drug conjugate delivers treatment
- How family members can help
- What people assume about sacituzumab govitecan
- Common questions about sacituzumab govitecan
The short answer
What is sacituzumab govitecan and who is it for?
Sacituzumab govitecan is an antibody-drug conjugate: an antibody joined to a powerful chemotherapy drug. The antibody seeks out a protein called Trop-2, which is found on the surface of most breast cancer cells, and delivers the chemotherapy directly to them. It is used for metastatic triple negative breast cancer after at least two earlier treatments, at least one of them for metastatic disease, and has been shown to help women live longer than standard chemotherapy in that setting. It is also used for some hormone receptor positive, HER2-negative metastatic cancers after hormone therapy and chemotherapy.
How it differs from ordinary chemotherapy
Because the antibody carries the drug to cells with Trop-2, a higher dose of chemotherapy reaches the cancer. The drug can also spread to nearby cancer cells, helping it work even when Trop-2 levels vary.
The side effects to plan for
Low white blood cells and loose motions are the most important side effects. Feeling sick, tiredness and hair loss are also common. Growth factor injections and anti-diarrhoea medicines help many people stay on treatment.
Who may not be suitable
People with very low blood counts, severe bowel problems or significant liver disease, and those with a known inherited problem breaking down the chemotherapy component. Your team checks these first.
This page gives general information only. Whether this treatment suits you is a decision for your oncologist.How it is given
What a treatment cycle usually involves
Blood tests before each dose
White cell counts are checked, because low counts may mean the dose is delayed.
Premedication
Anti-sickness medicines and medicines to prevent infusion reactions are given before the drip.
Infusion on days one and eight
It is given as a drip on the first and eighth days of a three-week cycle.
Observation
You are watched during and after the first infusions for reactions.
Continuing while it works
Cycles continue for as long as the cancer is controlled and side effects are manageable.
Side effects
Side effects most worth knowing about
Early reporting and preventive medicines make a real difference.
A low white cell count
Common and can raise infection risk. Growth factor injections may be used to help counts recover.
Loose motions
Common, sometimes severe. Start anti-diarrhoea medicine at the first loose stool and drink plenty of fluids.
Call if it does not settle.Feeling sick and tiredness
Usually managed with anti-sickness medicines and rest.
Hair loss
Hair thinning or loss is common during treatment.
Seek help urgently for
- Fever or shivering
- Loose motions with dizziness
- Breathing difficulty during infusion
Words you will hear
The vocabulary, in plain language
- Antibody-drug conjugate
- An antibody joined to a chemotherapy drug.
- Trop-2
- A protein on many breast cancer cells that the antibody targets.
- Triple negative
- Breast cancer without hormone receptors or extra HER2.
- Growth factor injections
- Injections that help white cells recover faster.
- UGT1A1
- A liver enzyme that breaks down the chemotherapy part of the drug.
- Line of treatment
- Each new treatment used after the previous one stops working.
Being straight with you
What this treatment can and cannot do
For metastatic triple negative breast cancer that has progressed after earlier treatments, sacituzumab govitecan offers a meaningful improvement over standard chemotherapy, both in controlling the cancer and in helping women live longer. It does not make metastatic cancer go away for good, and response times vary widely.
Side effects need active management
Low counts and loose motions can be significant. Dose delays, dose reductions and preventive medicines help most people continue safely.
Access can be difficult
This is an expensive treatment and may not be available everywhere in India. Ask your team about availability, support programmes and clinical trials.
Quality of life matters
Your oncologist weighs the benefit against the effect of treatment on daily life, and your priorities should shape the plan.
What this page cannot tell you
It cannot tell you how your cancer will respond. Ask your oncologist what they hope this treatment will achieve.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Managing side effects
Staying ahead of loose motions and infection
Two side effects shape daily life most on this treatment. Knowing what to do before they start helps prevent them becoming dangerous.
Loose motions
Keep anti-diarrhoea tablets at home and start them at the first loose stool, as your team advises. Drink oral rehydration solution, water and thin soups, and eat bland foods such as curd rice, bananas and toast. If loose motions continue for a day despite medicine, or you feel dizzy or pass little urine, call your team straight away.
Infection risk
When white counts are low, wash hands often, avoid crowds and people who are unwell, and eat freshly cooked food. Check your temperature if you feel unwell, and treat a fever as an emergency that needs same-day contact with your team.
Growth factor support
If counts drop repeatedly, injections may be given after each dose to help white cells recover, which can keep treatment on schedule.
In the treatment plan
Where sacituzumab govitecan fits
Treatment for metastatic breast cancer usually follows a sequence, and this drug has a specific place within it.
Triple negative cancers
It is typically used after at least two earlier treatments, sometimes after immunotherapy combinations or PARP inhibitors for BRCA carriers.
Hormone receptor positive cancers
It may be used after hormone therapies, including CDK4/6 inhibitors, and at least two lines of chemotherapy.
Other antibody-drug conjugates
For HER2-low cancers, trastuzumab deruxtecan may also be an option. Your oncologist will explain the order that suits you.
How it works
How an antibody-drug conjugate delivers treatment
Antibody-drug conjugates combine the precision of an antibody with the power of chemotherapy. Understanding the basic idea helps explain both why the treatment works and why it has the side effects it does.
Finding the target
The antibody part recognises Trop-2 on the surface of cancer cells and attaches to it. Trop-2 is present on most breast cancers, including triple negative cancers, which lack the usual targets for hormone or HER2 treatment.
Delivering the drug
Once attached, the cancer cell draws the conjugate inside, where the chemotherapy drug, called SN-38, is released and damages the cell's DNA. Some of the drug also passes into neighbouring cancer cells, a so-called bystander effect.
Why side effects still happen
Some Trop-2 is found on healthy tissues, and some of the chemotherapy reaches the rest of the body, which is why low blood counts and loose motions occur.
For families
How family members can help
Treatment for metastatic breast cancer often relies on family support, especially around infusion days and side effects.
On treatment days
Accompanying her to infusions, helping remember questions and arranging transport make long days easier.
Keeping a simple record
A notebook of temperatures, loose motions and medicines taken helps the team judge how treatment is going at each visit.
At home
Watching for fever, helping with fluids when loose motions start, and preparing gentle meals can prevent problems becoming serious.
Commonly believed
What people assume about sacituzumab govitecan
Targeted treatments have mild side effects.
This drug carries chemotherapy and can cause significant low counts and loose motions.
A Trop-2 test is needed before treatment.
Most breast cancers express Trop-2, and testing is not required before treatment.
Loose motions will settle on their own.
Start medicine early and call your team if they persist, as dehydration can be dangerous.
If earlier treatments failed, nothing else will work.
This drug was designed for people who had earlier treatments and has helped many live longer.
Questions we are asked
Common questions about sacituzumab govitecan
How long does each infusion take?
The first infusion is longer, often a few hours including observation. Later infusions are usually shorter if well tolerated.
Will I lose my hair?
Hair loss is common. Ask about scalp care and options.
Can I work during treatment?
Some people work with adjustments, though tiredness and infusion days may limit this.
Is it available in India?
Availability and cost vary. Ask your team about options, support programmes and trials.
What is a UGT1A1 test?
It checks how well your body breaks down the drug. It may be done if side effects are severe.
Can men receive this treatment?
Yes, if they have a suitable type of metastatic breast cancer.
Is pregnancy safe?
No. Effective contraception is needed during and after treatment.
Where can I read about my own drug?
Your oncology team will give you written information about your treatment. Use that as your main reference.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- New England Journal of Medicine — Sacituzumab govitecan in metastatic triple-negative breast cancer (ASCENT)
- National Cancer Institute — Sacituzumab govitecan-hziy
- Cancer Research UK — Sacituzumab govitecan (Trodelvy)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.